IXICO makes two boardroom changes

Going forward, IXICO will have two executive directors and three non-execs


Medical technology company IXICO PLC (LON:IXI) has made two top-level changes.

Chief financial officer Grant Nash, appointed to the role in April, joins the board with immediate effect.

WATCH: IXICO CFO Grant Nash joins board and discusses 'strong' 2019 performance

Tim Sharpington, the company’s senior independent director for the last six years, will step down at the end of the current financial year.

His role as senior independent director and head of the remuneration committee will be assumed by Mark Warne.

Following the changes, IXICO will have two executive directors and three non-execs.

Chief executive Giulio Cerroni said: "Grant's appointment to the board reflects the substantial contribution he has already made to IXICO since his appointment as CFO.

“He has brought strong financial leadership skills combined with a deep appreciation of operational excellence at a time of significant revenue growth and an accelerated path to profitability.

“Separately, I would like to thank Tim for all his counsel and guidance to me personally since I joined the company and wish him well for the future."

Quick facts: IXICO PLC

Price: 85 GBX

Market: AIM
Market Cap: £40.03 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...



IXICO PLC reports first year of profitability 'well ahead of expectations'

IXICO PLC's (LON:IXI) Giulio Cerroni sat down with Proactive London's Andrew Scott after reporting its first year of profitability since its admission to AIM . For the year ended 30 September, the neuroscience analytics firm swung to an underlying (EBITDA) profit of £500,000 from a £600,000...

on 4/12/19

2 min read